{"id":"https://openalex.org/W7215837102","doi":"https://doi.org/10.1158/1535-7163.34055560","title":"Figure S5 from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance","display_name":"Figure S5 from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance","publication_year":2026,"publication_date":"2026-10-02","ids":{"openalex":"https://openalex.org/W7215837102","doi":"https://doi.org/10.1158/1535-7163.34055560"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.34055560","doi":"https://doi.org/10.1158/1535-7163.34055560","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.34055560","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1535-7163.34055560","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5155609180","display_name":"Chengxi Li","orcid":"https://orcid.org/0009-0001-6304-7442","observed_orcids":["https://orcid.org/0009-0001-6304-7442"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chengxi Li","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0001-6304-7442","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069439605","display_name":"Yu\u2010Hsuan A. Chang","orcid":"https://orcid.org/0000-0003-2705-655X","observed_orcids":["https://orcid.org/0000-0003-2705-655X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yu-Hsuan Chang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2705-655X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5130704883","display_name":"Minori Maki","orcid":"https://orcid.org/0009-0002-7066-2184","observed_orcids":["https://orcid.org/0009-0002-7066-2184"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Minori Maki","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0002-7066-2184","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088108345","display_name":"Ikuko Omori","orcid":"https://orcid.org/0000-0002-8040-8764","observed_orcids":["https://orcid.org/0000-0002-8040-8764"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ikuko Omori","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8040-8764","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102884391","display_name":"Naru Sato","orcid":"https://orcid.org/0000-0003-0452-3194","observed_orcids":["https://orcid.org/0000-0003-0452-3194"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Naru Sato","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-0452-3194","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086241483","display_name":"Susumu Goyama","orcid":"https://orcid.org/0000-0002-9339-1826","observed_orcids":["https://orcid.org/0000-0002-9339-1826"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Susumu Goyama","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9339-1826","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054497666","display_name":"Toshio Kitamura","orcid":"https://orcid.org/0000-0001-7855-1767","observed_orcids":["https://orcid.org/0000-0001-7855-1767"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Toshio Kitamura","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7855-1767","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5079737516","display_name":"Yutaka Enomoto","orcid":"https://orcid.org/0000-0002-6346-9362","observed_orcids":["https://orcid.org/0000-0002-6346-9362"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yutaka Enomoto","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-6346-9362","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9042999744415283,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9042999744415283,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.06350000202655792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.00800000037997961,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":1.0},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":1.0},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9980000257492065},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.656000018119812},{"id":"https://openalex.org/keywords/bax","display_name":"Bax","score":0.9070000052452087},{"id":"https://openalex.org/keywords/bak","display_name":"Bak","score":0.9980000257492065},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.621999979019165},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7160000205039978},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.6600000262260437}],"concepts":[{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.9641000032424927},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.8065999746322632},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.7347000241279602},{"id":"https://openalex.org/C2994294914","wikidata":"https://www.wikidata.org/wiki/Q1645075","display_name":"Acquired resistance","level":3,"score":0.6909000277519226},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6891000270843506},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6330000162124634},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.5551000237464905},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.45879998803138733},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.4397999942302704},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.4043000042438507},{"id":"https://openalex.org/C127561419","wikidata":"https://www.wikidata.org/wiki/Q224527","display_name":"Downregulation and upregulation","level":3,"score":0.335099995136261},{"id":"https://openalex.org/C21200559","wikidata":"https://www.wikidata.org/wiki/Q7451068","display_name":"Sensitivity (control systems)","level":2,"score":0.321399986743927},{"id":"https://openalex.org/C2776192174","wikidata":"https://www.wikidata.org/wiki/Q18028978","display_name":"Mdm2","level":3,"score":0.31529998779296875},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.3124000132083893},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.3003999888896942},{"id":"https://openalex.org/C114851261","wikidata":"https://www.wikidata.org/wiki/Q12147416","display_name":"Drug resistance","level":2,"score":0.296099990606308},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.296099990606308},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.26829999685287476},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.2614000141620636},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.25040000677108765}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.34055560","doi":"https://doi.org/10.1158/1535-7163.34055560","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.34055560","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.34055560","doi":"https://doi.org/10.1158/1535-7163.34055560","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.34055560","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.8371999859809875,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7216099795","https://openalex.org/W7215717337","https://openalex.org/W7216473014","https://openalex.org/W7215958679","https://openalex.org/W7216300781","https://openalex.org/W7216037521","https://openalex.org/W7140672247","https://openalex.org/W7215995940","https://openalex.org/W7216296666","https://openalex.org/W7216337958"],"abstract_inverted_index":{"The":[0],"synergistic":[1],"effect":[2],"of":[3,13],"bortezomib":[4],"and":[5,15],"venetoclax":[6],"is":[7],"highly":[8],"dependent":[9],"on":[10],"the":[11],"expression":[12],"BAX":[14],"BAK":[16],"proteins.":[17]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2026-10-03T00:00:00"}